Canadian Addiction Treatment Centre (CATC) opioid agonist treatment cohort in Ontario, Canada.  Morin KA, Tatangelo M, Marsh D.  BMJ Open. 2024 Feb 24;14(2):e080790. doi: 10.1136/bmjopen-2023-080790. PMID: 38401902; PMCID: PMC10895228....

Insufficient Impact: Limited Implementation of Federal Regulatory Changes to Methadone and Buprenorphine Access in Arizona During COVID-19.  Meyerson BE, Bentele KG, Brady BR, Stavros N, Russell DM, Mahoney AN, Garnett I, Jackson S, Garcia R...

Navigating addiction treatment during COVID-19: policy insights from state health leaders. White SA, McCourt AD, Tormohlen KN, Yu J, Eisenberg MD, McGinty EE.  Health Aff Sch. 2024 Jan 29;2(2):qxae007. doi: 10.1093/haschl/qxae007. PMID: 383...

Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.  Hailu R, Mehrotra A, Huskamp HA, Busch AB, Barnett ML.  JAMA Netw Open. 2023 Jan 3;6(1):e2252381. doi: 10.1001/jamanetworkopen.2022....

Real-World Dispensing of Buprenorphine in California during Prepandemic and Pandemic Periods.  Wang Y, Chan A, Beuttler R, Fleming ML, Schneberk T, Nichol M, Lu H.  Healthcare (Basel). 2024 Jan 18;12(2):241. doi: 10.3390/healthcare1202...

The impact of changes in opioid dependency treatment upon COVID-19 transmission in Sydney, Australia: a retrospective longitudinal observational study.  Trevitt, B.T., Hayes, V., Deacon, R. et al  BMC Public Health 24, 349 (2...